Analytics Predict $74M Annual Treasury Inflow from Nomy Crypto Card Services, Driving NOMY Token Value Growth and Strengthening Ecosystem Stability
The early results from this test group, composed of high-net-worth individuals (HNWIs), have been promising, revealing a clear demand for this dual-functionality crypto card. The Nomy Crypto Card allows users to seamlessly spend their digital assets, while also providing them with the ability to access instant credit and liquidity based on the crypto holdings stored in their Nomy Finance account.
Key Findings from the Test Phase
The test phase has shown robust engagement, with over 100 crypto cards distributed among the VIP users. These early users have appreciated the flexibility and convenience offered by the card, which combines traditional payment methods with the ability to tap into crypto-backed liquidity instantly. Users can now access immediate credit and spend their digital assets without needing to liquidate them, which represents a major innovation in the intersection of crypto and traditional finance.
Projected Treasury Inflow: $74M to $122M Annually
Based on the data collected during the test phase and analysis of user behavior, Nomy Finance expects an annual inflow to the NOMY Treasury Pool ranging from $74 million to $122 million. This projection is based on the following factors: Strong Demand for the Nomy Crypto Card: There is significant interest in the Nomy Crypto Card, and it is anticipated that this demand will continue to grow as more users gain access to the product. 33% Buyback & Burn Program: Under the Buyback & Burn Program, 33% of profits generated from the card services will be directed towards bolstering the NOMY Treasury Pool and reducing circulating token supply through token burns.
Increased User Adoption: As the crypto card is made available to a wider audience, user adoption is expected to grow rapidly, further driving the inflow into the treasury.
Implications for NOMY Token's Value and Ecosystem Growth
The projected annual inflow of $74M to $122M will significantly strengthen the NOMY Treasury Pool, creating greater backing for each token and ensuring its scarcity through reduced circulating supply. As more profits from the Buyback & Burn Program flow into the treasury, the NOMY token will benefit from both increased demand and enhanced scarcity, driving long-term value appreciation for token holders.
The integration of instant credit and crypto-backed liquidity with the Nomy Crypto Card ensures that users can tap into the full potential of their crypto holdings while maintaining liquidity, creating a seamless experience between the crypto world and traditional financial systems.
Public Launch and Future Projections
As the test phase concludes, Nomy Finance is preparing for the public launch of the Nomy Crypto Card, which will be available to a broader audience. The team anticipates a surge in adoption, which will lead to even higher inflows into the NOMY Treasury Pool. The dual-functionality of the card — combining both credit and debit services — positions it as a game-changer in the crypto-finance space.
Executive Summary
The success of the Nomy Crypto Card test phase, along with the Buyback & Burn Program, highlights a promising future for the NOMY token and the Nomy Finance ecosystem. With projections of $74M to $122M annual inflow to the treasury, the NOMY Treasury Pool will continue to grow, ensuring long-term value for token holders and furthering Nomy Finance's mission to create a sustainable, user-driven ecosystem.
As the crypto card program continues to scale, Nomy Finance is poised to strengthen its position at the forefront of crypto innovation — providing users with a seamless and rewarding way to interact with their digital assets.
Contact Details:
Alejandro Mendez
Growth & Community Relations Lead
[email protected]
Disclaimer: This press release is provided by 'Nomyfi'. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining related opportunities involves significant risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector--including cryptocurrency, NFTs, and mining--complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. Speculate only with funds that you can afford to lose. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility.
Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Martinrea International Inc (MRETF) Q2 2025 Earnings Call Highlights: Strong Financial ...
Adjusted Operating Income: $86.1 million, up from $81.6 million in Q2 of last year. Adjusted Operating Income Margin: 6.8%, up 50 basis points year over year. Free Cash Flow (before IFRS 16 lease payments): $72 million, up from $51.7 million in Q2 of last year. Free Cash Flow (including IFRS 16 lease payments): $57.9 million. Adjusted Net Earnings Per Share: $0.66, up from $0.58 in Q2 of 2024. Net Debt: Decreased by approximately $73 million to $792 million. Net Debt to Adjusted EBITDA Ratio: 1.5x, down from 1.64x in Q1. 2025 Outlook: Total sales of $4.8 billion to $5.1 billion, adjusted operating income margin of 5.3% to 5.8%, and free cash flow of $125 million to $175 million. New Business Awards: $40 million in annualized sales, with $18 million from Stellantis and $22 million from Volkswagen and Volvo trucks. Warning! GuruFocus has detected 3 Warning Signs with MRETF. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Martinrea International Inc (MRETF) reported a strong second quarter with stable production levels, good profits, operating margin, and free cash flow. The company achieved notable margin improvements compared to the first quarter, driven by operational enhancements and negotiated commercial recoveries. Martinrea's machine learning initiatives, including adaptive welding software and AI vision systems, have resulted in significant cost savings and efficiency improvements. The company has been awarded new business worth $40 million in annualized sales, indicating a healthy pipeline and growth potential. Martinrea is on track to meet its 2025 outlook, with strong free cash flow generation and a solid balance sheet, maintaining a net debt to adjusted EBITDA ratio of 1.5x. Negative Points The company faces some tariff exposure, particularly from Tier 2 suppliers and parts affected by steel and aluminum tariffs, although it is considered manageable. Production sales are expected to be lower in the second half of the year due to typical seasonal patterns, which may impact margins. There are uncertainties regarding the impact of tariffs and the strength of the US economy in the second half of the year. Commercial recoveries in Europe have been limited, and the timing of these negotiations is somewhat out of the company's control. The company is maintaining a minimal footprint in the Rest of the World segment, which can result in profit swings due to changes in volumes and commercial settlements. Q & A Highlights Q: Can you provide additional commentary on the back-half margin guide, considering the strong margins despite lower sales in North America? A: Peter Cirulis, CFO: The second half will be impacted by seasonal adjustments, with production levels expected to be lower. There were some one-time favorable effects in Q2 that won't repeat in the second half, including contractual price reductions with certain customers. However, we expect a strong performance in the third quarter, with some opacity in the fourth. Q: Are there specific facilities in North America driving productivity and efficiency improvements? A: Pat D'Eramo, CEO: We don't focus on specific facilities, but our lean manufacturing journey is showing results across the board. Some plants are particularly advanced, and our machine learning initiatives are contributing to improvements. Overall, our operations are performing well globally. Q: Will there be any commercial recoveries in Europe in the second half of the year? A: Peter Cirulis, CFO: Commercial recoveries are somewhat unpredictable in terms of timing, but we expect some issues to be resolved in the second half. Over time, we anticipate fewer recoveries as the industry normalizes. Q: How do you view the impact of tariffs on your North American operations, given the strong margins? A: Peter Cirulis, CFO: There was a tariff headwind in Q2, but it was manageable. We expect to recover a large extent of this impact by year-end. The strong margins are also supported by our operational improvements and commercial activities. Q: With discussions on production reshoring, what are the implications for your facilities in Canada and Mexico? A: Pat D'Eramo, CEO: It depends on the source of the work. If it's new work from Asian or European OEMs, we will place it where it makes logistical sense. For work moving within North America, our existing footprint is well-positioned to handle it. This could create opportunities for our Canadian facilities. Q: What is your outlook on CapEx, given the recent trends? A: Peter Cirulis, CFO: We are comfortable with a $300 million CapEx target, but it could vary depending on the cadence of our launches and program extensions. We aim to align CapEx with depreciation. Q: How do you view the valuation of Martinrea compared to US peers, and would you consider re-domiciling to the US? A: Robert Wildeboer, Executive Chairman: We acknowledge the valuation discount and have bought back shares. Re-domiciling has tax implications, but we are aware of the value and will consider different strategies. We believe our shares are undervalued, which is why we've been buying them back. Q: What are your thoughts on the investment in NanoXplore and the potential of graphene? A: Robert Wildeboer, Executive Chairman: We believe graphene has a promising future and have used it in leading-edge products. While we don't use a large quantity, it contributes to our profitability. We are optimistic about its potential applications and the recognition of its value. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
42 minutes ago
- Yahoo
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...
Research and Development Expenses: $2.1 million for Q2 2025, compared to $15.1 million for Q2 2024. General and Administrative Expenses: $8.6 million for Q2 2025, compared to $7.3 million for Q2 2024. Net Loss: $26.9 million or $0.9 per share for Q2 2025, compared to $20.9 million or $0.9 per share for Q2 2024. Cash and Cash Equivalents: $312.8 million as of June 30, 2025. Follow-on Financing Proceeds: $230 million from May 2025, including full exercise of underwriters' option. Refinanced Loan: New debt facility of $50 million upfront with Trinity Capital, deferring principal payments by over 2.5 years. Warning! GuruFocus has detected 4 Warning Signs with TSHA. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Taysha Gene Therapies Inc (NASDAQ:TSHA) has obtained alignment with the FDA and Health Canada to proceed with initiating their REVEAL pivotal trial for TSHA-102, indicating strong regulatory progress. The company reported positive clinical data supporting the therapeutic potential of TSHA-102, with all 10 patients in Part A of the REVEAL trials gaining or regaining developmental milestones. TSHA-102 is designed to target the genetic root cause of Rett syndrome, leveraging a clinically proven AAV9 vector and a minimally invasive lumbar intrathecal injection method. The company completed a public follow-on offering, resulting in total gross proceeds of $230 million, extending their cash runway into 2028. Taysha Gene Therapies Inc (NASDAQ:TSHA) has a defined path to registration for TSHA-102, with a pivotal trial underway and a strengthened balance sheet. Negative Points The company reported a net loss of $26.9 million for the three months ended June 30, 2025, compared to a net loss of $20.9 million for the same period in 2024. General and administrative expenses increased to $8.6 million for the three months ended June 30, 2025, primarily due to higher legal and professional fees. There are no currently approved therapies that treat the underlying genetic root cause of Rett syndrome, highlighting the urgency and challenge of developing effective treatments. The company faces risks and uncertainties that may cause actual results to differ materially from forward-looking statements, as noted in their SEC filings. The pivotal trial design relies on a novel regulatory pathway, which may present challenges in terms of regulatory approval and market acceptance. Q & A Highlights Q: Given there was a 100% response rate for the pivotal trial primary endpoint in Part A of the study, is this the bar for Part B in your view? A: Sean Nolan, CEO: The results from Part A are compelling, but maintaining a 100% response rate is challenging. The statistical plan for Part B uses a null hypothesis of 6.7%, meaning only 1 out of 15 patients might spontaneously gain or regain a milestone. The statistical bar is relatively low, around 33%, and the numbers from Part A are significantly above this threshold. Q: Are there certain time points where all milestones are occurring, or are additional ones seen over time? Have the benefits of the gene therapy plateaued? A: Elsa Rosignol, Director of Integrated Rett Syndrome Clinic: We see increasing improvements over time, not just at one visit. Gains occur at most follow-up visits, and some critical gains in daily functioning are not captured in the developmental milestone assessment but are still significant improvements. Q: How does your gene therapy differentiate from competitors, particularly regarding study design and primary endpoints? A: Sean Nolan, CEO: Our approach is unique, focusing on clinically meaningful and objective gains in activities of daily living. We've worked with regulators to establish a new paradigm in assessing clinical efficacy through milestone gains. This approach is supported by KOLs, advocacy groups, and regulators, emphasizing the therapy's impact on quality of life. Q: Would you expect any pushback on using your interim readout to support BLA filing, given your competitor's feedback on a 6-month endpoint? A: Sean Nolan, CEO: Our interim analysis approach is data-driven, based on robust support from Part A data. We've discussed this with the FDA, focusing on further refinements of the analysis rather than overturning key trial design elements. We feel confident about our position. Q: Can you characterize any changes from Part A CMC material batch to Part B, specifically regarding full to empty capsid ratio? How many patients can you supply with commercial-scale material? A: Sean Nolan, CEO: We've aligned with the FDA that Part A and pivotal material are analytically comparable. We've made the product for the pivotal trial with the commercial process at scale. Our cash runway into 2028 allows us to build commercial inventory as needed, ensuring we're well-positioned on the CMC side. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
New York Times
44 minutes ago
- New York Times
New York City Companies All but Stopped Hiring in First Half of the Year
Employers in New York City significantly reduced hiring in the first half of the year, adding just 956 private-sector jobs, the city's slowest growth in payrolls outside a recession in decades. During the same period last year, companies in the city hired 66,000 additional workers, according to data from the city's Office of Management and Budget. But companies have since slowed their hiring, and major industries that fuel New York's economy — finance and insurance; hospitality; and retail — have shed jobs. Around the country, the labor market has started showing cracks as the effects of President Trump's economic policies begin to settle in. Other large cities have also seen sluggish job growth, with metro areas like Los Angeles, San Francisco and San Jose all losing a small number of jobs so far this year. 'The New York City economy has gone sideways so far this year,' said Mark Zandi, the chief economist of Moody's Analytics. 'New York is a leading indicator, and the flattening of employment is now showing up nationally.' The sharp slowdown in the New York City's labor market followed a resurgence last year in the local economy, which emerged slowly from the pandemic but reached a record level of employment with record bonuses for Wall Street workers. Now, the labor market in the largest municipal economy in the country appears notably weaker. The pace of job growth this year is the slowest since 2003, excluding the pandemic and the Great Recession. Want all of The Times? Subscribe.
